دورية أكاديمية
أعرض في EDS

Molecular mechanisms of microRNA-216a during tumor progression.

التفاصيل البيبلوغرافية
العنوان: Molecular mechanisms of microRNA-216a during tumor progression.
المؤلفون: Hamidi AA; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Taghehchian N; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Zangouei AS; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Akhlaghipour I; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Maharati A; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Basirat Z; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Moghbeli M; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Meysam_moghbeli@yahoo.com.; Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Meysam_moghbeli@yahoo.com.
المصدر: Cancer cell international [Cancer Cell Int] 2023 Feb 05; Vol. 23 (1), pp. 19. Date of Electronic Publication: 2023 Feb 05.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101139795 Publication Model: Electronic Cited Medium: Print ISSN: 1475-2867 (Print) Linking ISSN: 14752867 NLM ISO Abbreviation: Cancer Cell Int Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مستخلص: MicroRNAs (miRNAs) as the members of non-coding RNAs family are involved in post-transcriptional regulation by translational inhibiting or mRNA degradation. They have a critical role in regulation of cell proliferation and migration. MiRNAs aberrations have been reported in various cancers. Considering the importance of these factors in regulation of cellular processes and their high stability in body fluids, these factors can be suggested as suitable non-invasive markers for the cancer diagnosis. MiR-216a deregulation has been frequently reported in different cancers. Therefore, in the present review we discussed the molecular mechanisms of the miR-216a during tumor progression. It has been reported that miR-216a mainly functioned as a tumor suppressor through the regulation of signaling pathways and transcription factors. This review paves the way to suggest the miR-216a as a probable therapeutic and diagnostic target in cancer patients.
(© 2023. The Author(s).)
References: Sci Rep. 2014 Jul 01;4:5511. (PMID: 24981574)
BMC Cancer. 2011 Jul 13;11:293. (PMID: 21752268)
PLoS One. 2013 Oct 02;8(10):e76402. (PMID: 24098490)
Cancer Lett. 2007 Jun 28;251(2):199-210. (PMID: 17129668)
Fundam Clin Pharmacol. 2019 Aug;33(4):397-404. (PMID: 31119784)
J Pathol. 2013 Aug;230(4):441-52. (PMID: 23625826)
Int J Oncol. 2016 Mar;48(3):965-74. (PMID: 26708293)
Oncogene. 2005 Mar 31;24(14):2375-85. (PMID: 15674322)
Exp Ther Med. 2018 Jan;15(1):777-784. (PMID: 29399086)
PLoS One. 2015 Aug 10;10(8):e0135128. (PMID: 26258411)
Front Oncol. 2021 Nov 11;11:772134. (PMID: 34858852)
Oncotarget. 2017 Jul 26;8(39):65946-65956. (PMID: 29029484)
Mol Carcinog. 2017 Mar;56(3):877-885. (PMID: 27533647)
J Surg Oncol. 2009 Dec 15;100(8):725-31. (PMID: 19722233)
J Hematol Oncol. 2020 Aug 17;13(1):113. (PMID: 32807225)
Hum Cell. 2020 Oct;33(4):1281-1293. (PMID: 32860589)
Br J Cancer. 2003 May 6;88(9):1400-2. (PMID: 12778068)
BMC Cancer. 2022 Jul 19;22(1):790. (PMID: 35850748)
Mol Biol Rep. 2022 Nov;49(11):10609-10615. (PMID: 35715607)
Cell Death Dis. 2020 Apr 21;11(4):260. (PMID: 32317622)
Autophagy. 2018;14(4):671-684. (PMID: 28980855)
Biochem Biophys Res Commun. 2018 Jul 2;501(4):885-892. (PMID: 29763606)
BMC Cancer. 2017 Mar 16;17(1):201. (PMID: 28302118)
Int J Oncol. 2014 Oct;45(4):1401-11. (PMID: 25050916)
Int J Oncol. 2015 Feb;46(2):459-64. (PMID: 25405282)
Cancer Res. 2011 Mar 1;71(5):1989-98. (PMID: 21363926)
Cell Stem Cell. 2013 Feb 7;12(2):193-203. (PMID: 23395444)
Nucleic Acids Res. 2017 Mar 17;45(5):2687-2703. (PMID: 28168301)
Cell Commun Signal. 2022 Mar 9;20(1):27. (PMID: 35264191)
Front Pharmacol. 2020 May 20;11:733. (PMID: 32508653)
Cancer Res. 2017 Oct 15;77(20):5445-5451. (PMID: 28807941)
Lab Invest. 2013 Dec;93(12):1276-87. (PMID: 24145239)
Semin Cancer Biol. 2021 Oct;75:1-2. (PMID: 33894382)
Cell Death Dis. 2018 Jan 24;9(2):85. (PMID: 29367594)
BMC Cancer. 2021 Oct 7;21(1):1085. (PMID: 34620126)
Science. 1994 Apr 1;264(5155):95-8. (PMID: 8140422)
Nat Rev Cancer. 2005 Sep;5(9):726-34. (PMID: 16148885)
Cancer Res. 2008 May 15;68(10):3752-8. (PMID: 18483258)
Genes Dis. 2015 May 27;2(3):240-246. (PMID: 30258867)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Cell Rep. 2019 Aug 20;28(8):2037-2047.e4. (PMID: 31433981)
Cell Mol Biol Lett. 2021 Apr 07;26(1):13. (PMID: 33827418)
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14005-12. (PMID: 26823712)
Cancer Cell Int. 2022 Feb 10;22(1):71. (PMID: 35144601)
PLoS One. 2014 May 07;9(5):e95993. (PMID: 24804649)
Exp Hematol. 2011 May;39(5):558-69. (PMID: 21300134)
Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2469-2475. (PMID: 30964173)
Nature. 2011 Jul 04;476(7360):293-7. (PMID: 21727895)
Blood. 2013 Mar 28;121(13):2474-82. (PMID: 23335370)
Cell. 2008 Jan 11;132(1):27-42. (PMID: 18191218)
Nat Rev Genet. 2016 Jan;17(1):47-62. (PMID: 26666209)
Nat Commun. 2014 Nov 04;5:5232. (PMID: 25366117)
J Clin Neurosci. 2010 Nov;17(11):1359-61. (PMID: 20685122)
Stem Cell Res Ther. 2019 Jul 29;10(1):219. (PMID: 31358061)
Genes Environ. 2021 Jun 7;43(1):21. (PMID: 34099061)
Cancer Manag Res. 2019 Jul 24;11:6981-6993. (PMID: 31440087)
Mol Med Rep. 2018 Jan;17(1):699-704. (PMID: 29115550)
Clin Exp Metastasis. 2011 Mar;28(3):261-70. (PMID: 21184145)
Trends Cancer. 2017 Jan;3(1):56-71. (PMID: 28718426)
Oncotarget. 2018 Dec 14;9(98):37216-37228. (PMID: 30647855)
Nat Rev Cancer. 2006 May;6(5):392-401. (PMID: 16572188)
Oncotarget. 2013 Dec;4(12):2512-22. (PMID: 24318272)
Cancer Cell Int. 2021 Apr 15;21(1):213. (PMID: 33858435)
Front Cell Dev Biol. 2020 May 08;8:348. (PMID: 32457911)
Aging (Albany NY). 2020 Sep 21;12(18):18192-18208. (PMID: 33021963)
Anticancer Res. 2014 Mar;34(3):1449-55. (PMID: 24596393)
Exp Cell Res. 2017 Oct 15;359(2):319-326. (PMID: 28782557)
Biomed Pharmacother. 2017 Apr;88:459-468. (PMID: 28122312)
Cancer Sci. 2007 Nov;98(11):1666-77. (PMID: 17727684)
Front Cell Dev Biol. 2021 Jan 21;9:631623. (PMID: 33585487)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
Biosci Rep. 2018 Aug 29;38(4):. (PMID: 30061175)
Cancers (Basel). 2020 Jul 20;12(7):. (PMID: 32698360)
EMBO J. 2012 Jun 13;31(12):2685-96. (PMID: 22617424)
PLoS One. 2011;6(11):e26866. (PMID: 22096502)
Blood. 2012 Dec 6;120(24):4720-32. (PMID: 23018638)
Neoplasia. 2015 Sep;17(9):723-734. (PMID: 26476080)
J Ovarian Res. 2020 Jul 25;13(1):84. (PMID: 32711584)
Oncogene. 2006 Aug 17;25(36):4975-85. (PMID: 16568083)
J Natl Cancer Inst. 2013 Sep 18;105(18):1402-16. (PMID: 23990668)
Autophagy. 2017 May 4;13(5):820-833. (PMID: 28409693)
Front Cell Dev Biol. 2021 Nov 30;9:786728. (PMID: 34917620)
Cell Death Differ. 2012 Jan;19(1):107-20. (PMID: 21760595)
PLoS One. 2015 Nov 16;10(11):e0143150. (PMID: 26571030)
Genes Dev. 2007 Nov 15;21(22):2861-73. (PMID: 18006683)
Cancer Cell. 2018 Mar 12;33(3):463-479.e10. (PMID: 29455927)
Oncotarget. 2017 Jul 26;8(41):70097-70115. (PMID: 29050264)
Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9506-9516. (PMID: 31773719)
Cell Tissue Res. 2010 Jan;339(1):269-80. (PMID: 19693543)
J Cell Biochem. 2018 Feb;119(2):1755-1766. (PMID: 28786533)
Mol Cancer Res. 2018 Dec;16(12):1952-1964. (PMID: 30082484)
Organogenesis. 2008 Apr;4(2):68-75. (PMID: 19279717)
Nat Cell Biol. 2011 Mar;13(3):317-23. (PMID: 21336307)
Am J Transl Res. 2016 Aug 15;8(8):3387-97. (PMID: 27648129)
Oncol Lett. 2016 Apr;11(4):2339-2346. (PMID: 27073477)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
Int Endod J. 2013 Feb;46(2):128-36. (PMID: 22788664)
BMC Cancer. 2017 Dec 7;17(1):832. (PMID: 29216867)
Genomics. 2000 Sep 15;68(3):253-63. (PMID: 10995567)
Exp Ther Med. 2017 Oct;14(4):3720-3726. (PMID: 29042969)
Cell Biol Int. 2022 Jun;46(6):863-877. (PMID: 35297539)
Oncogene. 2007 May 14;26(22):3279-90. (PMID: 17496922)
J Clin Pathol. 2007 Nov;60(11):1216-21. (PMID: 17965220)
Cell Mol Biol Lett. 2019 Jun 28;24:46. (PMID: 31297133)
Nat Rev Cancer. 2017 Jan 27;17(2):93-115. (PMID: 28127048)
Balkan Med J. 2021 May;38(3):171-176. (PMID: 33377748)
Biomed Pharmacother. 2020 Feb;122:109707. (PMID: 31918278)
Nat Rev Cancer. 2014 Jan;14(1):13-25. (PMID: 24505617)
Metab Brain Dis. 2022 Feb;37(2):489-499. (PMID: 34792707)
Oncol Lett. 2019 Nov;18(5):4377-4384. (PMID: 31611946)
Am J Cancer Res. 2020 Apr 01;10(4):1115-1129. (PMID: 32368389)
Cell Death Dis. 2013 Apr 18;4:e601. (PMID: 23598413)
Hepatology. 2013 Aug;58(2):629-41. (PMID: 23471579)
Oncol Res. 2017 Sep 21;25(8):1317-1327. (PMID: 28256193)
Br J Cancer. 2018 Jan;118(1):88-97. (PMID: 29123266)
Cancer Control. 2018 Jan-Mar;25(1):1073274818769849. (PMID: 29651883)
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13783-8. (PMID: 16945912)
J Cell Physiol. 2020 Dec;235(12):9718-9728. (PMID: 32401366)
Oncotarget. 2017 Oct 10;8(60):101922-101935. (PMID: 29254214)
Bioengineered. 2021 Dec;12(2):11376-11389. (PMID: 34852712)
Hepatology. 2015 May;61(5):1755-7. (PMID: 25677471)
Mol Cancer. 2010 Apr 14;9:76. (PMID: 20398285)
Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52. (PMID: 17717517)
Gastroenterology. 2016 Jul;151(1):180-193.e12. (PMID: 27003603)
J Cell Physiol. 2019 Aug;234(8):12884-12896. (PMID: 30569514)
Pharmacol Ther. 2014 May;142(2):258-69. (PMID: 24362082)
Cancers (Basel). 2019 Oct 22;11(10):. (PMID: 31652660)
Cancer Treat Rev. 2018 Nov;70:178-189. (PMID: 30227299)
Front Oncol. 2021 Mar 23;11:622073. (PMID: 33842327)
Small GTPases. 2016 Oct;7(4):207-221. (PMID: 27628050)
Cell Signal. 2014 Nov;26(11):2350-7. (PMID: 25093807)
Genes Dev. 2008 Jul 15;22(14):1962-71. (PMID: 18579750)
Cell Res. 2010 Jul;20(7):748-62. (PMID: 20548331)
Hum Mol Genet. 2017 Dec 15;26(24):4836-4848. (PMID: 29036432)
Recent Results Cancer Res. 2016;207:39-72. (PMID: 27557534)
Drug Discov Today. 2016 Apr;21(4):598-615. (PMID: 26723915)
Cancers (Basel). 2021 Dec 10;13(24):. (PMID: 34944834)
Biosci Rep. 2018 Sep 28;38(5):. (PMID: 29884766)
Biomolecules. 2020 Dec 08;10(12):. (PMID: 33302540)
Cell. 2015 Nov 5;163(4):811-28. (PMID: 26544935)
Exp Biol Med (Maywood). 2021 Jan;246(2):142-152. (PMID: 33023331)
Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):375-82. (PMID: 18974621)
Int J Oncol. 2019 Apr;54(4):1195-1208. (PMID: 30968146)
Front Pharmacol. 2022 Mar 24;13:821344. (PMID: 35401182)
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1591-1599. (PMID: 30840282)
J Ovarian Res. 2021 Sep 30;14(1):127. (PMID: 34593006)
Onco Targets Ther. 2020 Nov 04;13:11327-11336. (PMID: 33177840)
Oncol Rep. 2014 Dec;32(6):2824-30. (PMID: 25220761)
Nature. 2010 Jan 28;463(7280):474-84. (PMID: 20110991)
Int J Cancer. 2017 May 15;140(10):2298-2309. (PMID: 28213952)
Cell Mol Biol Lett. 2021 Aug 23;26(1):39. (PMID: 34425750)
Cell. 1994 Mar 11;76(5):821-8. (PMID: 7510216)
FEBS Lett. 2015 Aug 4;589(17):2224-32. (PMID: 26149212)
J Biol Chem. 2016 Dec 16;291(51):26427-26434. (PMID: 27821587)
Prostate. 2019 Feb;79(3):320-330. (PMID: 30488530)
Exp Cell Res. 2006 Jan 1;312(1):73-85. (PMID: 16288740)
Transl Cancer Res. 2020 Apr;9(4):2648-2659. (PMID: 35117624)
Cell Res. 2008 Oct;18(10):997-1006. (PMID: 18766170)
J Cell Physiol. 2018 Dec;233(12):9447-9457. (PMID: 30136280)
FEBS Lett. 2009 Sep 3;583(17):2701-9. (PMID: 19631211)
Trends Cell Biol. 2010 Aug;20(8):453-60. (PMID: 20627573)
J Cell Biochem. 2019 Jun;120(6):10310-10322. (PMID: 30556161)
IUBMB Life. 2021 Jun;73(6):866-882. (PMID: 33759343)
Open Life Sci. 2020 Jul 27;15(1):532-543. (PMID: 33817241)
J Cancer. 2022 Mar 21;13(6):1882-1894. (PMID: 35399723)
Int J Hematol. 2013 Jun;97(6):726-34. (PMID: 23613270)
Semin Cancer Biol. 2022 May;80:1-17. (PMID: 31866476)
Gene. 2020 Jul 15;747:144648. (PMID: 32251703)
Oncotarget. 2017 Oct 4;8(51):88870-88881. (PMID: 29179483)
Am J Cancer Res. 2018 Mar 01;8(3):476-488. (PMID: 29637002)
J Transl Med. 2019 Apr 8;17(1):116. (PMID: 30961610)
Cancer Sci. 2011 Oct;102(10):1756-60. (PMID: 21679342)
Diagn Pathol. 2014 Mar 12;9:55. (PMID: 24621074)
Arch Biochem Biophys. 2018 Jan 1;637:1-8. (PMID: 29126969)
Oncol Rep. 2015 Sep;34(3):1557-64. (PMID: 26134156)
Drug Resist Updat. 2015 Jan;18:1-17. (PMID: 25554624)
Cancer Manag Res. 2018 Oct 18;10:4735-4745. (PMID: 30425570)
Cancer Manag Res. 2019 May 31;11:5075-5089. (PMID: 31213919)
Cancer Cell Int. 2021 Aug 21;21(1):439. (PMID: 34419060)
Int J Biol Sci. 2020 Jul 19;16(14):2612-2627. (PMID: 32792860)
Mol Cancer Ther. 2017 Aug;16(8):1511-1520. (PMID: 28468776)
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9248-53. (PMID: 17517622)
Oncol Res. 2018 Jan 19;26(1):157-171. (PMID: 28835317)
Oncogenesis. 2018 Aug 9;7(8):57. (PMID: 30089773)
Cell Signal. 2008 Sep;20(9):1662-70. (PMID: 18582561)
Aging Cell. 2016 Apr;15(2):370-9. (PMID: 26750654)
Evid Based Complement Alternat Med. 2021 Jul 22;2021:6675208. (PMID: 34335834)
Biomark Res. 2022 Jun 4;10(1):40. (PMID: 35659780)
Clin Cancer Res. 2017 Jan 1;23(1):298-310. (PMID: 27407092)
Chin J Cancer Res. 2017 Jun;29(3):237-252. (PMID: 28729775)
Cell Biosci. 2020 Jan 14;10:6. (PMID: 31956395)
Clin Cancer Res. 2007 Jul 15;13(14):4042-5. (PMID: 17634527)
Int J Mol Sci. 2020 Mar 27;21(7):. (PMID: 32230799)
Cell Death Dis. 2017 Oct 12;8(10):e3103. (PMID: 29022909)
Onco Targets Ther. 2019 Jun 12;12:4621-4629. (PMID: 31354295)
Eur J Pharmacol. 2019 Jun 5;852:189-197. (PMID: 30876979)
Nat Med. 2004 Jan;10(1):48-54. (PMID: 14702634)
Int J Immunopathol Pharmacol. 2015 Mar;28(1):36-44. (PMID: 25816404)
Oncol Rep. 2020 Nov;44(5):1971-1984. (PMID: 32901882)
J Cell Physiol. 2019 Jun;234(6):9408-9416. (PMID: 30430564)
Onco Targets Ther. 2017 May 23;10:2701-2709. (PMID: 28579808)
Oncotarget. 2015 Sep 22;6(28):25533-74. (PMID: 26325180)
Cancer Res. 2017 Jul 1;77(13):3513-3526. (PMID: 28522750)
فهرسة مساهمة: Keywords: Cancer; Diagnosis; Marker; MicroRNA-216a; Prognosis; Treatment
تواريخ الأحداث: Date Created: 20230205 Latest Revision: 20230208
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9899407
DOI: 10.1186/s12935-023-02865-2
PMID: 36740668
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2867
DOI:10.1186/s12935-023-02865-2